Evaluation of serum dickkopf-1 as a novel biomarker for hepatocellular carcinoma | ||||
| Journal of Current Medical Research and Practice | ||||
| Volume 4, Issue 1, January 2019, Page 91-97 PDF (1002.08 K) | ||||
| DOI: 10.4103/JCMRP.JCMRP_130_18 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Neveen A.M. Hassan; Ebtsam F. Mohammed; Zainab G. Mahran; Zeinab A. Abd Elhamed; Aya M. Ebrahim; Nahed A. Makhlouf | ||||
| Abstract | ||||
| Background Hepatocellular carcinoma (HCC) is a common worldwide cancer. α-Fetoprotein (AFP) is a routinely used biomarker for HCC diagnosis, but with reduced clinical applicability due to low sensitivity and specificity. Dickkopf-1 (DKK-1) is vital in the differentiation, survival, apoptosis, and cell death. DKK-1 has a potential oncogenic role in carcinogenesis. Aim In this study, we evaluated the diagnostic and prognostic performance of serum DKK-1, AFP, and their combination in HCC. Patient and methods This study was done on 40 HCC patients, 24 liver cirrhosis patients, and 16 age-matched and sex-matched healthy controls. The patients were selected from the Tropical Medicine and Gastroenterology Department, Al-Rajhi Liver Hospital. Results The optimum cutoff for DKK-1 in HCC patients versus liver cirrhosis and control groups was more than 331 pg/ml with a sensitivity of 80.0% and specificity of 87.5%. The optimum cutoff for AFP was more than 8 IU/ml (sensitivity 77.5%, specificity 85.0%). The combination of the two markers had the best sensitivity (92.5%) in the diagnosis of HCC patients. Conclusion DKK-1 levels was significantly higher in newly diagnosed HCC patients than in the nonmalignant control group. The combination of the two markers (DKK-1 and AFP) enhanced the sensitivity. | ||||
| Keywords | ||||
| α-fetoprotein; Dickkopf-1; Hepatocellular carcinoma | ||||
|
Statistics Article View: 37 PDF Download: 15 |
||||
